IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v22y2021i8d10.1007_s10198-021-01335-8.html
   My bibliography  Save this article

Health state utility values by cancer stage: a systematic literature review

Author

Listed:
  • Mir-Masoud Pourrahmat

    (Evidinno Outcomes Research Inc.)

  • Ashley Kim

    (GRAIL, Inc.)

  • Anuraag R. Kansal

    (GRAIL, Inc.)

  • Marg Hux

    (Evidinno Outcomes Research Inc.)

  • Divya Pushkarna

    (Evidinno Outcomes Research Inc.)

  • Mir Sohail Fazeli

    (Evidinno Outcomes Research Inc.)

  • Karen C. Chung

    (GRAIL, Inc.)

Abstract

Objectives Cancer diagnoses at later stages are associated with a decrease in health-related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based HRQOL and can vary based on cancer type, stage, treatment, and disease progression. Detecting and treating cancer at earlier stages may lead to improved HRQOL, which is important for value assessments. We describe published HSUVs by cancer type and stage. Methods A systematic review was conducted using Embase, MEDLINE®, EconLit, and gray literature to identify studies published from January 1999 to September 2019 that reported HSUVs by cancer type and stage. Disutility values were calculated from differences in reported HSUVs across cancer stages. Results From 13,872 publications, 27 were eligible for evidence synthesis. The most frequent cancer types were breast (n = 9), lung (n = 5), colorectal (n = 4), and cervical cancer (n = 3). Mean HSUVs decreased with increased cancer stage, with consistently lower values seen in stage IV or later-stage cancer across studies (e.g., − 0.74, − 0.44, and − 0.51 for breast, colorectal, and cervical cancer, respectively). Disutility values were highest between later-stage (metastatic or stage IV) cancers compared to earlier-stage (localized or stage I–III) cancers. Conclusions This study provides a summary of HSUVs across different cancer types and stages that can inform economic evaluations. Despite the large variation in HSUVs overall, a consistent decline in HSUVs can be seen in the later stages, including stage IV. These findings indicate substantial impairment on individuals’ quality of life and suggest value in early detection and intervention.

Suggested Citation

  • Mir-Masoud Pourrahmat & Ashley Kim & Anuraag R. Kansal & Marg Hux & Divya Pushkarna & Mir Sohail Fazeli & Karen C. Chung, 2021. "Health state utility values by cancer stage: a systematic literature review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(8), pages 1275-1288, November.
  • Handle: RePEc:spr:eujhec:v:22:y:2021:i:8:d:10.1007_s10198-021-01335-8
    DOI: 10.1007/s10198-021-01335-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01335-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-021-01335-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Xingdong Chen & Jeffrey Gole & Athurva Gore & Qiye He & Ming Lu & Jun Min & Ziyu Yuan & Xiaorong Yang & Yanfeng Jiang & Tiejun Zhang & Chen Suo & Xiaojie Li & Lei Cheng & Zhenhua Zhang & Hongyu Niu & , 2020. "Non-invasive early detection of cancer four years before conventional diagnosis using a blood test," Nature Communications, Nature, vol. 11(1), pages 1-10, December.
    2. Tromme, Isabelle & Devleesschauwer, Brecht & Beutels, Philippe & Richez, Pauline & Leroy, Laurence & Baurain, Jean-Francois & Legrand, Catherine, 2014. "Health-related quality of life in patients with melanoma expressed as utilities and disability weights," LIDAM Reprints ISBA 2014038, Université catholique de Louvain, Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA).
    3. Angela C. Tramontano & Deborah L. Schrag & Jennifer K. Malin & Melecia C. Miller & Jane C. Weeks & J. Shannon Swan & Pamela M. McMahon, 2015. "Catalog and Comparison of Societal Preferences (Utilities) for Lung Cancer Health States," Medical Decision Making, , vol. 35(3), pages 371-387, April.
    4. Michaël Schwarzinger & Stéphane Luchini & Sylvain Baillot & Mélina Bec & Lynda Benmahammed & Caroline Even & Lionnel Geoffrois & Florence Huguet & Béatrice Le Vu & Laurie Lévy-Bachelot & Yoann Pointre, 2019. "Estimating health state utility from activities of daily living in the French National Hospital Discharge Database: a feasibility study with head and neck cancer," Post-Print hal-02270971, HAL.
    5. Louis Matza & Karen Chung & Kate Brunt & John Brazier & Ada Braun & Brooke Currie & Andrew Palsgrove & Evan Davies & Jean-Jacques Body, 2014. "Health state utilities for skeletal-related events secondary to bone metastases," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 7-18, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Xiao Zhou & Zhen Cheng & Mingyu Dong & Qi Liu & Weiyang Yang & Min Liu & Junzhang Tian & Weibin Cheng, 2022. "Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    2. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    3. Steven D Criss & Lauren Palazzo & Tina R Watson & Adelle M Paquette & Keith Sigel & Juan Wisnivesky & Chung Yin Kong, 2020. "Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-15, January.
    4. Mary L. Stackpole & Weihua Zeng & Shuo Li & Chun-Chi Liu & Yonggang Zhou & Shanshan He & Angela Yeh & Ziye Wang & Fengzhu Sun & Qingjiao Li & Zuyang Yuan & Asli Yildirim & Pin-Jung Chen & Paul Winogra, 2022. "Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    5. Tiantian Wang & Peilong Li & Qiuchen Qi & Shujun Zhang & Yan Xie & Jing Wang & Shibiao Liu & Suhong Ma & Shijun Li & Tingting Gong & Huiting Xu & Mengqiu Xiong & Guanghua Li & Chongge You & Zhaofan Lu, 2023. "A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

    More about this item

    Keywords

    Health state utility; Disutility; Cancer; Cancer stage; Breast cancer; Lung cancer; Colorectal cancer; Cervical cancer; Systematic literature review;
    All these keywords.

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General
    • I00 - Health, Education, and Welfare - - General - - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:22:y:2021:i:8:d:10.1007_s10198-021-01335-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.